CardioMech AS Announces Series A Financing for its Transcatheter Mitral Valve Repair Technology

August 5, 2020—CardioMech AS announced it has closed on its Series A financing to support the process of a first-in-human feasibility trial for the company’s catheter-based transfemoral, transseptally delivered mitral valve repair technology to reduce or eliminate mitral regurgitation.

CardioMech AS is a privately held company based in Minneapolis, Minnesota, that is developing transcatheter technology to treat patients with moderate-to-severe or severe, symptomatic degenerative mitral regurgitation caused by prolapse or flail.

The $18.5 million financing round is led by a nondisclosed strategic investor together with health care specialist investor Hadean Ventures and Investinor.